Exploratory subgroup analysis from INNOVATE-3 finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback